Sugi Predict

Sugi Predict / Targets / SMYD3

SMYD3

Histone-lysine N-methyltransferase SMYD3 · Q9H7B4 · SMYD3 on Sugi Atlas →

48,503 patent compounds predicted against SMYD3, 24,519 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL26301 SCHEMBL26301 0.71 17/20
SCHEMBL493819 SCHEMBL493819 0.52 17/20
SCHEMBL622063 SCHEMBL622063 0.56 16/20
SCHEMBL261651 SCHEMBL261651 0.57 15/20
SCHEMBL572810 SCHEMBL572810 0.62 14/20
SCHEMBL572811 SCHEMBL572811 0.62 14/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL572762) 0.60 14/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL572763) 0.60 14/20
SCHEMBL357812 SCHEMBL357812 0.52 14/20
SCHEMBL45469 SCHEMBL45469 0.58 13/20
SCHEMBL688076 SCHEMBL688076 0.55 13/20
SCHEMBL473560 SCHEMBL473560 0.50 13/20
SCHEMBL473561 SCHEMBL473561 0.50 13/20
SCHEMBL688478 SCHEMBL688478 0.54 12/20
SCHEMBL265042 SCHEMBL265042 0.48 12/20
SCHEMBL265043 SCHEMBL265043 0.48 12/20
SCHEMBL688890 SCHEMBL688890 0.59 10/20
SCHEMBL414839 SCHEMBL414839 0.51 10/20
SCHEMBL105058 SCHEMBL105058 0.50 10/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL447045) 0.50 10/20

Clinical trials — most relevant to SMYD3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
MR Antagonist and LSD1 PHASE4ACTIVE_NOT_RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Decitabine in Treating Patients With Myelofibrosis PHASE2ACTIVE_NOT_RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Clinical and Genomic Registry of MDS in Asia nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
COPENHAGEN Minipuberty Study nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Novel Strategy for Early Detection of Esophageal Squamous Cell Carcinoma nanRECRUITING
Impact of Weight Loss on the Human Sperm Epitranscriptome nanACTIVE_NOT_RECRUITING
Smurf2 Gene Expression in Urinary Tract Tumors nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Natural History Study of Smith-Magenis Syndrome nanACTIVE_NOT_RECRUITING
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Effect of DNMT SNPs on DNA Methylation in Primary ITP nanUNKNOWN
Phenomics and Genomics of Clozapine Pharmacotherapy nanUNKNOWN
FoxO3a and PU.1 in Acute Lymphoblastic Leukemia nanUNKNOWN
Methylation of DNA in Children and Adolescents With Type 1 Diabetes Mellitus (METHYLDIAB) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SMYD3 binder may also engage these)

ProteinNameSimilarity
Q9CWR2 — 1.000 Q9CWR2 →
Q6GN68 — 0.994 Q6GN68 →
Q7ZXV5 — 0.992 Q7ZXV5 →
Q5RGL7 — 0.991 Q5RGL7 →
C3RZA1 — 0.990 C3RZA1 →
SMYD2 N-lysine methyltransferase SMYD2 0.988 landscape →
Q0P585 — 0.987 Q0P585 →
Q5BJI7 — 0.986 Q5BJI7 →
Q7M6Z3 — 0.986 Q7M6Z3 →
Q8R5A0 — 0.986 Q8R5A0 →
E1C5V0 — 0.985 E1C5V0 →
Q8BTK5 — 0.982 Q8BTK5 →
Q7XJS0 — 0.978 Q7XJS0 →
PRMT9 Protein arginine N-methyltransferase 9 0.978 landscape →
Q08C84 — 0.977 Q08C84 →
Q8NB12 — 0.976 Q8NB12 →
P97443 — 0.976 P97443 →
Q95LY5 — 0.976 Q95LY5 →
E1BMP7 — 0.976 E1BMP7 →
Q3TYX3 — 0.976 Q3TYX3 →
D3ZQF4 — 0.975 D3ZQF4 →
Q6P3X3 — 0.975 Q6P3X3 →
POLQ DNA polymerase theta 0.975 landscape →
A6QQ71 — 0.975 A6QQ71 →
Q8VE09 — 0.975 Q8VE09 →
Q96BT7 — 0.974 Q96BT7 →
Q95K79 — 0.974 Q95K79 →
Q80Y20 — 0.974 Q80Y20 →
Q6NTR1 — 0.974 Q6NTR1 →
Q5ZIJ9 — 0.973 Q5ZIJ9 →